EUVIMEDEUVIMED entdecken
Crossref

Discovery of GSI526: a potent IRAK4-targeting PROTAC degrader with efficient degradation and suppression of inflammatory signaling

Bingjie Yin, Zhishuo Gao, Yan Ma, Zhuoyue Li, Mengjun Ma

Bioorganic & Medicinal Chemistry Letters · 2026-09 · 138 · 130680

DOI: 10.1016/j.bmcl.2026.130680 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2026-09. Verfasst von Bingjie Yin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, …. Hauptthemen laut MEDLINE: Interleukin-1 Receptor-Associated Kinases, Drug Discovery, Inflammation, Protein Kinase Inhibitors. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Natural Science Foundation of Qingdao, National Natural Science Foundation of China, Shandong Province Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin-1 receptor-associated kinase 4 (IRAK4) is a promising therapeutic target for inflammatory diseases. However, inhibition of its kinase activity alone often results in incomplete blockade of inflammatory signaling and limited therapeutic efficacy. To address this limitation, we designed and synthesized a novel proteolysis-targeting chimera (PROTAC) aimed at degrading IRAK4. Among the synthesized compounds, GSI526 emerged as a potent degrader, demonstrating efficient IRAK4 degradation in THP-1 cells with a DC₅₀ of 40.17 nM. Mechanistic studies confirmed that GSI526 acts via the ubiquitin-proteasome system, effectively suppressing the IRAK4-mediated NF-κB and MAPK signaling pathways. Furthermore, GSI526 exhibited a favorable preliminary safety profile. Collectively, these findings identify GSI526 as a promising IRAK4-targeting degrader, offering an alternative therapeutic strategy and a candidate for further drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-1 Receptor-Associated KinasesDrug DiscoveryInflammationProtein Kinase InhibitorsHumansSignal TransductionProteolysis Targeting ChimeraNF-kappa BProteolysisStructure-Activity RelationshipMolecular StructureTHP-1 Cells

Stichwörter der Autor:innen

DegraderIRAK4MAPKNF-κBPROTAC

Substanzen

Interleukin-1 Receptor-Associated KinasesProteolysis Targeting ChimeraIRAK4 protein, humanNF-kappa BProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China.
  • Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China; Center for Targeted Protein Degradation and Drug Discovery, Oce…

Förderung

  • Natural Science Foundation of Qingdao
  • National Natural Science Foundation of China
  • Shandong Province Natural Science Foundation

Zitieren

APA

Yin, B., Gao, Z., Ma, Y., Li, Z., & Ma, M. (2026). Discovery of GSI526: a potent IRAK4-targeting PROTAC degrader with efficient degradation and suppression of inflammatory signaling. Bioorganic & Medicinal Chemistry Letters, 138, 130680. https://doi.org/10.1016/j.bmcl.2026.130680

Vancouver

Yin B, Gao Z, Ma Y, Li Z, Ma M. Discovery of GSI526: a potent IRAK4-targeting PROTAC degrader with efficient degradation and suppression of inflammatory signaling. Bioorganic & Medicinal Chemistry Letters. 2026;138:130680. doi:10.1016/j.bmcl.2026.130680

BibTeX
@article{Yin2026,
  author = {Yin, Bingjie and Gao, Zhishuo and Ma, Yan and Li, Zhuoyue and Ma, Mengjun},
  title = {Discovery of GSI526: a potent IRAK4-targeting PROTAC degrader with efficient degradation and suppression of inflammatory signaling},
  journal = {Bioorganic & Medicinal Chemistry Letters},
  year = {2026},
  volume = {138},
  pages = {130680},
  doi = {10.1016/j.bmcl.2026.130680}
}
Kostenlos starten →